Article Per Year (5 Year)
p-Index From 2020 - 2025
0.817
P-Index
This Author published in this journals
All Journal Jurnal Respirologi Indonesia Jurnal Respirasi (JR) Narra J
Aditya Wirawan
Department Of Pulmonology And Respiratory Medicine, Faculty Of Medicine, Universitas Indonesia
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Challenges on tuberculosis care in health care facilities during COVID-19 pandemic: Indonesian perspective Wira Winardi; Hendra Wahyuni; Moulid Hidayat; Aditya Wirawan; Fariz Nurwidya; Mohammad N. Uddin; Mohamad Yusup
Narra J Vol. 2 No. 2 (2022): August 2022
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v2i2.80

Abstract

Indonesia is among the top three countries globally with the highest tuberculosis  burden. During the past decades, Indonesian health authorities have struggled to improve tuberculosis care quality in health care facilities by optimizing the regulation and strengthening the private sector contributions. The coronavirus disease 2019 (COVID-19) pandemic has hardly affected the Indonesian health care system, including the National Tuberculosis Control Program. While the end of the COVID-19 pandemic in Indonesia is uncertain, the measure to control tuberculosis must not be weakened. Early identification and measurement of the problem size are essential to decide the most appropriate approach to maintain the sustainability of National Tuberculosis Control Program, particularly in health care facilities during the COVID-19 pandemic. This article points out the possible threats to the sustainability of TB care in Indonesia during the COVID-19 pandemic, including some approaches to overcome those problems.
Remdesivir in COVID-19: A Retrospective Analysis of Remdesivir Effectiveness and the Relation with Blood Type Variation Elsa Vera Denida Purba; Retnosari Andrajati; Nadia Farhanah Syafhan; Aditya Wirawan
Jurnal Respirologi Indonesia Vol 43, No 1 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i1.392

Abstract

identify the profile of the effectiveness of Remdesivir (RDV) therapy and its relationship to blood type variations in COVID-19 patients at Universitas Indonesia Hospital (RSUI).Methods: Variations in blood types were examined for their influence on the effectiveness in Covid-19 infected patients with RDV as an antiviral treatment. Data for this study were acquired at RSUI using a retrospective cross-sectional method. The sample is infected patients with COVID-19 from January 2021 to December 2021 who received RDV therapy. The parameters of the effectiveness of the treatment was a reduction of minimally 2 points on the WHO Clinical Progression Scale after 14 days of Remdesivir administration.Results: RDV effectiveness percentage shows 57.5% of patients experienced clinical improvement. The analysis results of the effect of blood type variations on clinical outcomes significantly affect the effectiveness of RDV therapy (OR: 1.705, 95% CI: 1.091–2.665; p = 0.019) but insignificant in terms of mortality status (OR: 0.654, 95% CI: 0.383–1.117; p = 0.120).Conclusion: Blood type variations significantly affected the effectiveness of RDV therapy in infected COVID-19 patients.
Effectiveness of COVID-19 Antivirus Therapy and Its Relationship with Vaccination: A Retrospective Analysis Andi Utari Prasetya Ningrum; Retnosari Andrajati; Nadia Farhanah Syafhan; Aditya Wirawan
Jurnal Respirologi Indonesia Vol 43, No 3 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i3.434

Abstract

Background: COVID-19 is known to have infected more than a million people. COVID-19 can be treated with antivirals. Besides antiviral drugs, vaccination becomes one of the strategies to suppress the spread of COVID-19. This study aimed to analyze the effectiveness of antivirus and the relationship between vaccination and the effectiveness of the two antiviral therapies in COVID-19 patients based on improvements in the patient's clinical condition, length of stay, and mortality.Methods: This study used a retrospective cohort design conducted at the Universitas Indonesia Hospital, Depok, Indonesia. Data were taken from medical records and hospital databases from January 2021 to August 2022. The antivirals in this study were remdesivir and favipiravir. The samples were divided into two groups, namely the vaccinated and unvaccinated groups.Results: The factor affecting the effectiveness of remdesivir and favipiravir therapy was the severity of COVID-19. It was shown that vaccination had a significant effect on improving clinical conditions, reducing length of stay, and reducing mortality in patients treated with remdesivir who had been vaccinated compared to those who had not been vaccinated. In patients who received favipiravir therapy and were vaccinated, it also showed an effect on improving clinical conditions, length of stay, and mortality compared to patients who were not vaccinated, although the results were not statistically significant.Conclusion: Vaccination had a positive effect on the effectiveness of remdesivir and favipiravir in COVID-19 patients, which could improve the patient's clinical condition in a better direction, as well as reduce length of hospitalization and mortality.
Effectivity of Telemonitoring Toward Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis Ananda Pipphali Vidya; Jansen Jayadi; Karen Elliora Utama; Kenneth Ren; Aditya Wirawan; Nyityasmono Tri Nugroho
Jurnal Respirasi Vol. 10 No. 2 (2024): May 2024
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v10-I.2.2024.168-177

Abstract

Introduction: Chronic obstructive pulmonary disorder (COPD) is the third-leading cause of death worldwide. COPD treatment is essential to manage and attenuate the progression of symptoms. Home-based telemonitoring interventions showed several promises in increasing COPD patients' quality of life (QoL) and outcomes. However, various results were obtained in recent studies, making a secondary research presence needed to establish clear risks and benefits. This study aimed to analyze the effect of telemonitoring on QoL among COPD patients. Methods: This study used the Preferred Reporting Items of Systematic Review and Meta-Analysis (PRISMA) reporting guidelines on several databases from February until April 2023. We performed screening and selection, followed by data extraction and quantitative analysis with Review Manager 5.4 Software. The risk of bias assessment was performed using the RoB 2.0 Cochrane tool. Results: Ten randomized controlled trials (RCTs), mostly low-risk of bias, were included. We found a reduction in Saint George's Respiratory Questionnaire (SGRQ) score (mean difference (MD) -1.13 [95% CI -4.23, 1.97; p = 0.47]) and Hospital Anxiety and Depression Scale (HADS) for anxiety (MD-0.16 [95% Cl -0.96, 0.63; p = 0.69]). There was no significant effect of HADS on depression and EuroQol-5 Dimension (EQ-5D). Conclusion: This study suggests that telemonitoring improves QoL in COPD patients, especially for SGRQ and HADS anxiety scores. We suggest a larger number of studies to evaluate the effect of telemonitoring on depression and anxiety. We also encourage the integration of telemedicine with the present care system to achieve the best beneficial outcome for patients.
Co-Authors Ananda Pipphali Vidya Andi Utari Prasetya Ningrum Elsa Vera Denida Purba Fariz, Nurwidya Hendra Wahyuni Jansen Jayadi Karen Elliora Utama Kenneth Ren Mohamad Yusup Mohammad N. Uddin Moulid Hidayat Nadia Farhanah Syafhan Nyityasmono Tri Nugroho Retnosari Andrajati Retnosari Andrajati Wira Winardi